Systematic reviews of GLP1 worth reading

Want to get refreshed on GLP1 research into drugs like Ozempic, Wegovy, Mounjaro, Zepbound and others? Start here.

Systematic reviews of GLP1 worth reading
Glasses sitting on a notebook

There is a lot of research coming out about GLP1 Receptor Agonists like Ozempic, Wegovy, Mounjaro, Zepbound and others – it's hard to keep up.

🍃
Don't know what a GLP1 Receptor Agonist is, or how drugs like Ozempic, Mounjaro, Wegovy, or Zepbound work?

Check out our quick explainer

There are different kinds of research to read/keep up to date with:

  • Clinical Trials
    • These are the most important – they represent actual rigorous use and measurement of the effects of the drugs, and with a large enough sample size and good methods, can produce evidence of efficacy or risks
  • Studies
    • Studies are deep dives into methods of action, or information related to GLP1s that could explain or point to the how and why they work. Studies can often draw on trials and other sources of data and research to piece together an insight.
  • Case Studies
    • Case studies represent reports of particular instances that are often prescriptive or contain insight/information that is worth disseminating. Case studies usually provide some interesting insight based on a small number of patients that is worth keeping in mind for medical practitioners (doctors, nurses, health professionals).
  • Meta analysis / Review
    • Meta analysis usually consists of gathering the results of many different studies, trials, and pieces of research – combining them to find out if a certain idea is true, or even just to make it easier for people to keep up with all the advancements in the field.

Today, we're going to look at some great meta analysis/review papers that are worth reading and summarize the progress in the field.

If you're not sure where to start, check out this paper:

Glucagon-like peptide 1 (GLP-1) paper

It was written in 2019, but captures much of the thoughts and the research in the field before Ozempic was in much of the popular discourse. People weren't talking about GLP1 so much back in 2019 – and the thoughts of the medical professionals of the time are worth reading again.

GLP1's role in addictive behavior

Another common refrain is the possible role of GLP1 in addictive behavior – there's great analysis/review on that as well:

The role of glucagon-like peptide 1 (GLP-1) in addictive disorders

While there's no "smoking gun" per-say – the problem of addiction is very complicated, and these researchers have done the hard work of assembling the current research and trying to find signal in the noise.